Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.32 |
| ▸ | IKBKB | O14920 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.30 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4259466 | 0.71 | FAAH (0.40) | KMT2A | |
| SCHEMBL6484485 | 0.70 | HRH3 (0.33) | LMNAKMT2A | |
| SCHEMBL7524003 | 0.67 | NPC1 (0.36) | LMNAHCRTR1HCRTR2KMT2AP2RX7 | |
| Acetamide SCHEMBL1259199 | 0.64 | DHODH (0.48) | LMNAIKBKBKMT2A | |
| Acetone SCHEMBL18784619 | 0.63 | KMO (0.52) | LMNAKMT2A | |
| SCHEMBL6841467 | 0.63 | MAPT (0.46) | LMNAKMT2A | |
| SCHEMBL3626066 | 0.62 | — | — | |
| SCHEMBL15727864 | 0.62 | — | — | |
| Acetic Acid SCHEMBL734741 | 0.61 | KMO (0.56) | LMNAKMT2A | |
| Benzene SCHEMBL28772928 | 0.61 | KMO (0.56) | LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130101615-A1 | METHODS FOR PREVENTING OR TREATING A DISEASE OR CONDITION ASSOCIATED WITH MYCOBACTERIUM AVIUM SUBSPECIES PARATUBERCULOSIS | GREENSTEIN ROBERT J (US) | 2013-04-25 | — | — | US | disclosed |
| US-20090054380-A1 | Methods for diagnosing and treating a mycobacterium avium subspecies paratuberculosis infection | GREENSTEIN ROBERT J | 2009-02-26 | — | — | US | disclosed |
| US-20090012048-A1 | Methods for diagnosing and treating a mycobacterium avium subspecies paratuberculosis infection | GREENSTEIN ROBERT J | 2009-01-08 | — | — | US | disclosed |
| EP-0906088-B1 | LIPOSOMAL ANTINEOPLASTON THERAPIES WITH MARKEDLY IMPROVED ANTINEOPLASTIC ACTIVITY | BURZYNSKI STANISLAW R (US) | 2005-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130101615-A1 | METHODS FOR PREVENTING OR TREATING A DISEASE OR CONDITION ASSOCIATED WITH MYCOBACTERIUM AVIUM SUBSPECIES PARATUBERCULOSIS | HLA-DRB1, CD14, HLA-C | LMNA 3195/4885HCRTR1 3148/4885HCRTR2 3533/4885 |
| US-20090054380-A1 | Methods for diagnosing and treating a mycobacterium avium subspecies paratuberculosis infection | MAPT, MAP7, MAPK1 | LMNA 3504/4885HCRTR1 4533/4885HCRTR2 4606/4885 |
| US-20090012048-A1 | Methods for diagnosing and treating a mycobacterium avium subspecies paratuberculosis infection | MAPT, MAP7, MAPK1 | LMNA 3504/4885HCRTR1 4533/4885HCRTR2 4606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.